GROVIA LLC – Trademark Portfolio
Entity Type: 16
GROVIA LLC owns a portfolio of 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as GROVIA, BIOLINERS, and BIOSOAKER. Of these, 7 are registered. The portfolio spans 9 Nice Classification classes, led by Class 18 (Leather Goods) and Class 16 (Paper Goods). Headquartered in BOZEMAN, MT.
PO BOX 10911
BOZEMAN, MT 59719
Showing of trademarks Trademarks
Trademark Classifications
GROVIA LLC's trademark portfolio spans 9 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Leather and imitations of leather; animal skins, hides; trunks and travelling bags
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Advertising; business management; business administration; office functions
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does GROVIA LLC have?
GROVIA LLC has 10 U.S. trademarks filed with the USPTO. Of these, 7 registered, 3 cancelled.
What trademark classes does GROVIA LLC file in?
GROVIA LLC files trademarks across 9 Nice Classification classes. The most active classes are Class 18 (Leather Goods), Class 16 (Paper Goods), Class 35 (Advertising & Business), Class 3 (Cosmetics & Cleaning), Class 24 (Fabrics). Class 18 covers leather and imitations of leather; animal skins, hides; trunks and travelling bags.
What are GROVIA LLC's most well-known trademarks?
GROVIA LLC's registered trademark portfolio includes well-known marks such as GROVIA, BIOLINERS, and BIOSOAKER. These are among 7 currently registered trademarks in the portfolio.
What is GROVIA LLC's trademark registration success rate?
GROVIA LLC has a 70% trademark registration rate, with 7 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.